tiprankstipranks
Advertisement
Advertisement
Morning Movers: Abivax skyrockets following new obefazimod data
PremiumThe FlyMorning Movers: Abivax skyrockets following new obefazimod data
22d ago
Unicycive Therapeutics receives complete response letter from FDA for OLC NDA
Premium
The Fly
Unicycive Therapeutics receives complete response letter from FDA for OLC NDA
22d ago
H.C. Wainwright recommends taking advantage of Unicycive stock weakness
Premium
The Fly
H.C. Wainwright recommends taking advantage of Unicycive stock weakness
26d ago
Ramakanth Reiterates Buy on Unicycive, Sees De-Risked Path to FDA Approval with 12-Month $22 Price Target Unchanged
PremiumRatingsRamakanth Reiterates Buy on Unicycive, Sees De-Risked Path to FDA Approval with 12-Month $22 Price Target Unchanged
2M ago
Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim
Premium
The Fly
Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim
2M ago
Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
Premium
The Fly
Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
2M ago
3 Best Stocks to Buy Today, 3/18/2026, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Today, 3/18/2026, According to Top Analysts
4M ago
Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns
Premium
Ratings
Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns
4M ago
Unicycive Therapeutics management to meet with Piper Sandler
Premium
The Fly
Unicycive Therapeutics management to meet with Piper Sandler
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100